Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The cancer supportive care drugs market was valued at USD 21.67 Billion in 2025. It is poised to grow at a CAGR of 2.30% during the forecast period of 2026-2035, and reach USD 27.20 Billion by 2035. The market growth is driven by rising cancer prevalence, increasing demand for supportive care therapies, expanding oncology treatments, improving healthcare infrastructure, and growing adoption of biologics to manage treatment-related side effects globally.
Latest News on the Cancer Supportive Care Drugs Market (2026)
April 2026: AACR Reports Nine FDA Oncology Approvals in Q1 2026
The U.S. Food and Drug Administration issued nine oncology approvals in the first quarter of 2026, several of which are considered landmark and standard-of-care changing for cancer patients, according to the American Association for Cancer Research. The expanding therapeutic pipeline accelerates demand for adjacent supportive-care therapies including antiemetics, neutropenia drugs, and pain management agents across the global cancer supportive care drugs market.
March 2026: Pfizer Showcases Oncology Pipeline Driving Supportive Care Demand
Pfizer announced in March 2026 that it will present new data across its diverse oncology portfolio at the ASCO Annual Meeting from May 29 to June 2, 2026, in Chicago, including therapies driving downstream supportive care demand. The announcement reinforces accelerating clinical-development momentum across the global oncology landscape and durable expansion across the global cancer supportive care drugs market amid rising chemo and immunotherapy patient populations.
Key Market Trends and Insights
- By drug type, colony-stimulating factors segment is likely to dominate with 34% share in the historical period.
- By distribution channel, the hospital pharmacies segment is likely to lead, accounting for 51% share in the historical period.
- By geography, the North America segment is likely to dominate, capturing around 42% share in the historical period.
Market Size and Forecast
- Market Size (2025): USD 21.67 Billion
- Projected Market Size (2035): USD 27.20 Billion
- CAGR (2026-2035): 2.30%
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
-
In March 2026, the FDA approved nivolumab with chemotherapy for first-line Hodgkin lymphoma, expanding treatment access and options.
-
In February 2026, the WHO reported nearly 20 million annual cancer cases globally, highlighting rising burden and healthcare demand.
-
In February 2026, FDA approved zongertinib (Hernexeos) as a first-line lung cancer treatment, expanding eligible patient population significantly.
Compound Annual Growth Rate
2.3%
Value in USD Billion
2026-2035
*this image is indicative*
Cancer Supportive Care Drugs Market Overview
The market is expanding steadily, driven by rising global cancer incidence and increasing demand for therapies managing treatment-related side effects. Advancements in biologics and targeted supportive treatments are improving patient outcomes. Growing awareness, better access to oncology care, and expanding healthcare infrastructure continue to support adoption, contributing to sustained market growth worldwide. The market reached a value of approximately USD 21.67 Billion in 2025.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cancer Supportive Care Drugs Market Growth Drivers
Rising Global Cancer Burden Accelerating the Market Demand
Increasing cancer incidence and mortality worldwide remain key drivers fueling market expansion. For instance, in February 2026, the World Health Organization reported that nearly 20 million new cancer cases occur annually, with 37% (7.1 million) linked to preventable causes globally. This escalating burden strengthens demand for cancer burden management strategies, driving sustained adoption of supportive care therapies across global healthcare systems.
Cancer Supportive Care Drugs Market Trends
Key trends shaping the market include increasing biologics adoption, rising cancer prevalence, improved supportive therapies, and expanding access to oncology care globally.
Regulatory Advancements and First-Line Approvals Boosting the Market Landscape
Rising demand for advanced cancer therapies and increasing regulatory approvals are shaping market trends globally. For instance, in March 2026, the U.S. FDA approved nivolumab (Opdivo) with chemotherapy for first-line Hodgkin lymphoma treatment. This development strengthens clinical trials, accelerating innovation and expanding treatment access, thereby influencing supportive care demand across the oncology landscape.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cancer Supportive Care Drugs Market Segmentation
Market Breakup by Drug Type
- Antiemetic Drugs
- Analgesic Drugs
- Colony-stimulating Factors
- Bisphosphonates
- Anti-infective Drugs
- Anti-anemia Drugs
- Monoclonal Antibodies
- Others
Market Breakup by Cancer Type
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Blood cancer
- Others
Market Breakup by Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Specialty pharmacies
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Cancer Supportive Care Drugs Market Share
Hospital Pharmacies Segment Likely to Lead the Market by Distribution Channel
The hospital pharmacies segment is likely to lead the market by distribution channel, accounting for approximately 51% share during the forecast period. This dominance is supported by high patient inflow, integrated treatment delivery, and availability of specialized oncology therapies. Increasing reliance on drug distribution networks within hospital settings further strengthens accessibility, ensuring timely administration of supportive care treatments.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Cancer Supportive Care Drugs Market Analysis by Region
The North America segment is likely to dominate the market by region, holding around 42% share in the historical period. Growth is supported by advanced healthcare infrastructure, strong oncology treatment adoption, and high awareness levels. Increasing investments in healthcare infrastructure and access to innovative supportive therapies continue to reinforce the region’s dominant position globally.
Leading Players in the Cancer Supportive Care Drugs Market
The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
F. Hoffmann-La Roche AG
Founded in 1896 and headquartered in Basel, Switzerland, Roche is a global leader in pharmaceuticals and diagnostics. Its portfolio spans oncology, immunology, and supportive care, including antiemetics and biologics. The company emphasizes oncology therapeutics to improve cancer care outcomes. In 2025, Roche advanced multiple oncology pipeline programs and diagnostics integration initiatives.
HELSINN Healthcare SA
Established in 1976 and headquartered in Lugano, Switzerland, Helsinn focuses on supportive cancer care. Its portfolio includes antiemetics and cancer supportive therapies designed to improve patient quality of life. The company prioritizes supportive care drugs innovation in oncology settings. Recent updates highlight ongoing collaborations to expand global access to cancer supportive treatments.
Tesaro
Founded in 2010 and headquartered in Waltham, Massachusetts, Tesaro specializes in oncology-focused therapeutics. Its portfolio includes supportive care and cancer treatment products, notably antiemetics and PARP inhibitors. The company has contributed to cancer treatment advancements through innovative drug development. Tesaro was acquired by GSK, strengthening oncology portfolio expansion.
Novartis International AG
Founded in 1996 and headquartered in Basel, Switzerland, Novartis is a leading global pharmaceutical company. Its portfolio includes oncology drugs, supportive care therapies, and advanced biologics. The company focuses on targeted therapies to enhance treatment precision and outcomes. Novartis continues investments in innovative oncology pipelines and clinical research.
Other key players in the market are Heron Therapeutics, Merck & Co., Inc., and Amgen Inc.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Questions Answered in the Cancer Supportive Care Drugs Market Report
- What was the cancer supportive care drugs market value in 2025?
- What is the cancer supportive care drugs market forecast outlook for 2026-2035?
- What major factors aid the demand for cancer supportive care drugs market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major cancer supportive care drugs market trends?
- Which drug type is expected to dominate the market segment?
- Which cancer type is expected to dominate the market segment?
- Which distribution channel is expected to dominate the market segment?
- Who are the key players in the cancer supportive care drugs market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Cancer Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share